A lzheimer disease (AD) is the most common degenerative brain disorder, characterized by cognitive impairment and abnormal deposition of amyloid plaques and neurofibrillary tangles in the brain. The apolipoprotein E ε4 (APOE4) allele contributes the greatest attributable genetic risk for AD.
regions involved in AD during the predementia stage. In contrast, we present data to support DHA catabolism in the dementia stage. We hypothesize that DHA supplementation in APOE4 carriers can prevent or delay the onset of AD when the timing precedes the onset of neurodegeneration. We suggest 3 disease stages, delineated by specific biomarkers, to guide the evaluation of the differential efficacy of treatment.
Methods
We searched the PubMed database for original articles, systematic reviews, and meta-analyses of ω-3 studies in AD that were published before August 30, 2016. Our results included preclinical studies, cross-sectional studies, longitudinal cohorts, and randomized clinical trials. For preclinical studies, we discuss findings from a 2012 meta-analysis from Hooijmans et al. 11 For observational studies, we discuss key findings of cross-sectional and longitudinal cohorts and present summaries of these studies in the eTable in the Supplement. The results of a meta-analysis on ω-3 and AD incidence conducted by Zhang et al 12 are then discussed. For randomized clinical trials, we present summaries of key findings of 14 ω-3 trials in Table 1 and discuss conclusions of a Cochrane systematic review 27 from 2012 and a systematic review by Yurko-Mauro et al 28 from 2015. We then examine mechanistic studies that link APOE genotype with DHA metabolism to understand the effect of APOE4 on DHA brain delivery and discuss the role of recent advances in brain imaging.
Observations

Role of Long-term DHA Supplementation in the Prevention of AD in Animal Studies
Docosahexaenoic acid significantly affects hippocampal neuronal development and synaptic function in the developing hippocampus.
In embryonic neuronal cultures, DHA supplementation promotes neurite growth and synaptic protein expression. 29 Long-term deficiency of DHA in the diet led to learning impairment in an animal model. 30 A systematic review that focused on the effects of relatively long-term ω-3 supplementation (minimum period, 10% of an average total lifespan) in AD animal models reported significant reductions in detergent-insoluble amyloid levels and plaque burden and improved cognitive outcomes. 11 The largest beneficial effects were observed when DHA supplementation was started before initiating a toxic experimental model of AD (such as infusing Aβ peptide in the rat cerebral ventricle). Supplementation with DHA attenuated AD pathologic changes in APOE4 transgenic mouse models of AD 31 by restoring memory and learning and synaptic functions and reducing hippocampal Aβ42 levels to APOE3 levels. This finding underscores a role of long-term DHA supplementation in the prevention rather than in the treatment of AD, and that the AD phenotype in APOE4 transgenic mouse model can be prevented with DHA supplementation.
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Observational Studies Linking ω-3 Intake and Levels With Cognitive Outcomes
Most observational studies associate higher levels of seafood, ω-3 consumption, or ω-3 blood levels with decreased incidence of AD, better cognitive measures, or preserved brain volume in ADvulnerable regions (eTable in the Supplement). In general, observational studies investigated participants without evidence of cognitive impairment at baseline for a follow-up duration ranging from 2 to 20 years and evaluated outcomes such as AD incidence or cognitive decline. Zhang et al 12 summarized 21 of these studies in a metaanalysis of 181 580 participants, with 4438 dementia cases identified during follow-up ranging from 2.1 to 21 years. The authors concluded that a 1-serving/wk increment of dietary fish was associated with significantly lower risk for AD dementia (relative risk, 0.93; 95% CI, 0.90-0.95; P = .003).
Randomized Clinical Trials of ω-3s in AD Dementia and Predementia
The effects of ω-3 supplementation on cognitive outcomes in randomized clinical trials [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] have been mixed (Table 1) . Supplementation was not effective in the treatment of symptomatic AD. 13, 14 In studies that included participants with mild or no cognitive impairment, the results were mixed. A Cochrane review 27 in 2012 found no evidence to support ω-3 supplementation in cognitively healthy older individuals. In contrast, a 2015 meta-analysis that examined additional studies 28 concluded that ω-3 supplementation significantly improves episodic memory. In cognitively healthy individuals, 6 randomized clinical trials demonstrated better memory functions with ω-3 supplementation compared with placebo, [17] [18] [19] [20] 23, 24 whereas 6 trials reported no benefit. 15, 16, 21, 22, 25, 26 Some of these randomized clinical trials had limitations. For example, in 2 trials of cognitively healthy younger adults, the duration of follow up was less than 6 months. 21, 22 Some trials used low doses of ω-3. 21, 26 In 1 trial, no cognitive decline in the placebo and the ω-3 intervention arms was observed. 25 We suggest the following 4 factors that might explain these variable results: (1) limitations or differences in study design (eg, age, dose, or duration); (2) selection of participants who will not progress to AD dementia; (3) stage of disease at the time of ω-3 supplementation; and (4) baseline ω-3 consumption. Given the safety profile, availability, and affordability of ω-3 supplements, refining ω-3 interventions and trial designs to identify a population that might have a beneficial response is worthwhile.
Effect of APOE Genotype on the Association of ω-3 With Cognitive Outcomes
The APOE genotype often appears to affect the response to ω-3 supplementation, and, conversely, ω-3 supplementation can affect the influence of APOE genotype on AD symptoms, 13, 15, 19, [32] [33] [34] [35] [36] [37] [38] [39] although these results are inconsistent ( Table 2 ). Some observational studies do not reveal an effect of APOE status on the In some observational studies, the benefit of increased seafood or ω-3 consumption on cognition was restricted to APOE4 noncarriers [32] [33] [34] [35] and, in particular, those with limited seafood intake (<1 serving/wk). 32,33 The Alzheimer's Disease Cooperative Study (ADCS)-sponsored DHA trial reported a null effect on cognitive outcomes, but a preplanned analysis revealed a cognitive benefit (using the cognitive subscale of the Alzheimer Disease Assessment Scale) in the DHA treatment arm in APOE4 noncarriers. 13 In other studies, benefit was restricted to APOE4 carriers. 15, 19, 36, 37 The beneficial response in APOE4 carriers was In a cross-sectional study of deceased participants from the Rush Memory and Aging Project, 37 participants were free of dementia at study entry and underwent annual clinical neurologic evaluations and brain autopsy at death with a mean follow-up duration of 8 years. Individuals who were APOE4 carriers and consumed at least 1 meal of seafood per week or had higher intakes of long-chain ω-3 fatty acids had less AD neuropathologic changes compared with those who consumed lower amounts. A recent report in the ADCS-sponsored DHA clinical trial found that baseline cerebrospinal fluid (CSF) DHA levels were lower in APOE4 carriers compared with APOE2 carriers. 44 After treatment, lower DHA levels were observed in persons with more advanced brain disease as determined by the lowest tertile of CSF Aβ42 levels. 44 These findings agree with those of preclinical studies in 13-month-old, APOE-targeted replacement (TR) mice, where brain DHA levels were lower in APOE4-TR mice compared with APOE2-T R mice. 45 Accordingly, we propose a complex interaction between APOE4 status and disease stage such that the response to ω-3 supplementation depends on whether supplementation precedes the onset of neurodegeneration. These studies indicate that APOE4 is a modifiable AD risk factor, and that the effect of APOE4 on AD pathologic changes can be attenuated with DHA supplementation.
Mechanisms Underlying the Association of APOE4
With DHA Brain Uptake
Isoforms of APOE differ in structure from each other only at amino acids 112 and 158. The APOE2 allele has cysteine at both sites, the APOE4 allele has arginine at both positions, and the APOE3 allele contains cysteine at amino acid 112 and arginine at amino acid 158. Such minor differences give rise to variability in domain interactions with multiple molecules, including the low-density lipoprotein receptor, cell-surface heparin sulfate proteoglycans, adenosine triphosphatebinding cassette protein 1 (ABCA1), and low-density lipoproteinrelated proteins, as well as with protein stability and protein folding.
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Differences in the metabolism of APOE particles are likely directly related to APOE conformation and receptor binding. APOE2 exhibits a more stable conformation and has lower affinity to the lowdensity lipoprotein receptor, which may lead to decreased catabolism. In contrast, APOE4 has a less stable conformation, increased affinity to the low-density lipoprotein receptor, and increased catabolism.
Effect of APOE4 on DHA Transport Before the Onset of Neurodegeneration
Several mechanisms link APOE4 with reduced brain DHA metabolism. These mechanisms include (A) accelerated liver catabolism of DHA, (B) defective DHA transfer across the blood-brain barrier, and (C) hypolipidated or decreased APOE particle numbers, resulting in less efficient DHA transport ( Figure 1) . Evidence supports the contention that these APOE4 mechanisms operate before the onset of neurodegeneration. In APOE4 carriers, 13 C-DHA levels in plasma total lipids from 1 hour to 28 days after the dose were 31% lower compared with levels in APOE4 noncarriers. These findings suggest increased peripheral DHA catabolism, potentially limiting DHA availability to the brain in APOE4 carriers.
Blood-Brain Barrier Integrity Coupled With Transport of DHA to the Brain | A decrease in the ratio of CSF to plasma DHA was reported in patients with dementia at the lowest tertile of CSF Aβ42 levels. 44 Transgenic mouse models prone to brain amyloid deposition (3xTg-AD mice) demonstrated less delivery of carbon 14-labeled DHA across the blood-brain barrier compared with littermate controls. 50 The APOE4 allele is associated with breakdown in blood-brain barrier integrity. 51 Delivery of DHA to the brain and blood-brain barrier integrity are both regulated by the major facilitator superfamily domain-containing 2A transporter (MFSD2a). 52 The APOE4 allele may compromise the integrity of lipoprotein and MFSD2A transporter functions, providing a common mechanism for reduced DHA uptake and loss of blood-brain barrier integrity that associate with early stages of AD pathologic changes. Figure 3 illustrates the association between plasma DHA levels (using scaled DHA and amyloid deposition units to allow for comparison). The association of DHA with amyloid deposition in predementia but not clinical disease led to formulation of a timing hypothesis for a DHA intervention in preclinical APOE4 carriers. Based on these findings, we hypothesize that an intervention using highdose DHA supplementation in cognitively healthy APOE4 carriers can slow the rate of progression to prodromal or clinical AD.
Designing an Informative Clinical Trial in APOE4 Carriers
We propose classifying APOE4 carriers into 3 stages based on disease severity. Stage I represents the earliest predementia phase of the disease with evidence of brain imaging changes in ADvulnerable areas, but with subtle or no cognitive changes detectable. In this stage, brain DHA metabolism is altered by APOE4, and brain imaging or CSF biomarkers can be used to select at-risk individuals and monitor the efficacy of supplementation. Stage II represents an early prodromal stage with evidence of memory and/or executive decline but no significant impairment in activities of daily living. In this stage, long-term, high-dose DHA supplementation In the Alzheimer Disease Cooperative Study (ADCS)-sponsored DHA trial (A), 43 participants with dementia underwent lumbar puncture before randomization to placebo or DHA supplementation for 18 months. In contrast, the Aging Brain Study (ABS) (B) recruited cognitively healthy (CH) individuals to gain an understanding of risk factors for Alzheimer disease (AD). Sixty-one participants underwent Pittsburgh Compound B positron emission tomography to assess cerebral amyloidosis (including 13 apolipoprotein E ε4 [APOE4] carriers). Given the different methods of DHA level measurements and amyloid deposition indices in both studies, the units were scaled from −2 to 4 arbitrary scale units. Cerebrospinal fluid β-amyloid (Aβ) 42 peptide levels were inverted. Plasma DHA levels were not associated with amyloid deposition in the ADCS but were inversely associated with amyloid deposition in carriers and noncarriers of the APOE4 allele, which supports the timing hypothesis for DHA intervention in APOE4 carriers. Regression lines illustrate a significant inverse association between plasma DHA levels and brain amyloid deposition in the ABS and a nonsignificant association between baseline plasma DHA levels with brain amyloid deposition in the ADCS-sponsored DHA clinical trial.
nally for a mean of 4.5 years. The greatest difference in cognitive domains by APOE status was reflected by the word list memory measure. The divergence in memory outcomes between carriers and noncarriers appeared in their 60s in APOE4 heterozygotes and in their 50s in APOE4 homozygotes. Some evidence links ω-3 levels with some of the cognitive deficits observed in APOE4 carriers. Samieri )inAPOE4 carriers. The modest effect size of ω-3 supplementation on cognitive outcomes during the predementia stages highlights the challenge for smaller clinical trials to detect significant APOE genotype by treatment interactions.
Brain Imaging of APOE4 Carriers
APOE4 carriers at an increased risk of developing AD demonstrate brain differences in AD-vulnerable regions that are evident on several brain imaging modalities before any evidence of cognitive decline or AD-related brain neuropathologic changes. Of particular interest are APOE4-related changes that become more pronounced with age and are observed in regions associated with later cognitive decline. Progressive changes in these brain functions and structures can serve as useful diagnostic targets to guide the efficacy of interventions in the early predementia phase (stage I). 1. Incorporation of DHA into the brain has been quantified using 11 C-labeled DHA positron emission tomographic (PET) scans.
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Umhau et al 64 demonstrated a compensatory increase in brain DHA uptake in the alcohol withdrawal state. The DHA PET scans can be a useful tool to quantify the degree of brain DHA uptake in APOE4 carriers and inform whether supplementation can enhance brain uptake during the various stages of this disease. 2. Amyloid PET imaging can be used to define a preclinical AD stage in APOE4 carriers with amyloid deposition at AD-related brain areas. This amyloid deposition may appear 1 to 2 decades before the onset of symptoms. 
Conclusions
We propose that disease stage-related alterations in DHA transport affecting peripheral and central metabolism in APOE4 carriers should be considered when designing intervention studies. We hypothesize that DHA supplementation in APOE4 carriers can result in beneficial outcomes if the timing of the intervention precedes the onset of dementia. Given the safety profile, availability, and affordability of DHA, refining an interventional prevention study in APOE4 carriers is warranted. 
